IL10 and neoplasm: In an in vivo breast cancer model, Tα‐1 in conjunction with Epirubicin treatment markedly slowed down the growth of the tumor by decreasing IL10 produced by macrophages and increasing the quantity and quality of CD4+ and CD8+ T cells that infiltrate the tumor.